There was a trend of better OS in patients with IDH2 mutation (hazard ratio 0.563, 95% confidence interval 0.292 1.086, P=0.087).
In the adjusted analysis, the survival experience of carriers of the BRCA2 mutation was better than that of carriers of the BRCA1 mutation (hazard ratio 0.45, 95% confidence interval 0.26 to 0.81), but among patients treated with chemotherapy, the survival advantage for carriers of the BRCA2 mutation was attenuated (0.62, 0.30 to 1.31).
Both CD56 negative tumors (Hazard ratio: 2.6 (95% CI: 1.14-6.00); p = 0.019) and K-ras mutations (Hazard ratio: 4.74 (95% CI: 1.8-12.3); p = 0.001) contribute as significant independent negative prognostic factors for the PFS (table 3).
However, the presence of DNMT3A nonsynonymous variations (hazard ratio 1.229, P = 0.724), deleterious mutations, and R882 mutations (hazard ratio 2.285, P = 0.313 in both) did not affect OS significantly as well as increasing age and BM blasts, although the trend was toward to adverse prognosis.
In univariate analysis, prognostic significance for survival ( from metastases until death) was seen for BRAF mutations (Hazard Ratio HR 8.1, 95% CI 3.4-19 3.4-19n 12-only KRAS mutations (HR 1.62, 95% codon12-only high AREG mRNA expression only in KRAS wild type CRC (HR 0.47, 95% CI 0.3-0.7) and high EREG mutationsession irrespective of KRAS mutation status (HR 0.45, 95% CI 0.28-0.7).
The risk of eczema further increased with exposure to cats at birth among children with filaggrin gene mutations (hazard ratios 11.11 and 3.82, respectively).
Carrying this PALB2 mutation was also reported to be associated with reduced survival; comparing affected PALB2 mutation carriers, negative for HER2 expression, with a family history of breast cancer with affected non-carriers of BRCA1, BRCA2, or PALB2 mutations, the hazard ratio was estimated to be 4.57 (95% CI=1.96 10.64; P=0.0004) (Heikkinen et al, 2009).
In addition, survival improves with increasing log-transformed missense mutation count (univariate hazard ratio = 0.82, 95% CI = 0.69 to 0.98) for TCGA samples.
We confirmed that IDH mutation with a hazard ratio = 0.358 is an independent prognostic factor of good outcome.
By multivariate analysis, low BECN1 expression was significantly associated with shortened survival, even after adjustment for BRCA1 expression, age, tumor grade, tumor size, stage, intrinsic subtypes, TP53 mutation and treatment (hazard ratio 0.6 [0.4–0.9], P = 0.02) (Table 3).
Only SNP rs10771399 near PTHLH was associated with breast cancer risk for BRCA1 mutation carriers (per-allele hazard ratio (HR) = 0.87, 95% CI: 0.81 to 0.94, P-trend = 3 × 10-4).
